tesamorelin ipamorelin blend before and after: Frequently asked questions

First, verify reconstitution and storage protocol—peptides stored above 8°C or reconstituted incorrectly lose potency without visible degradation. Second, confirm dosing timing aligns with fasted states; administering either compound within 2 hours of a meal or in the presence of elevated insulin blunts GH release regardless of peptide quality. Third, obtain DEXA or MRI imaging to quantify visceral adipose tissue specifically—waist circumference and scale weight are unreliable for tracking VAT changes, and subcutaneous fat loss may be minimal even when visceral fat is decreasing significantly. If imaging confirms no VAT reduction and adherence is verified, consider baseline GH and IGF-1 testing to rule out pituitary resistance or pre-existing GH hypersecretion that would blunt response.

Clinical data beyond 26 weeks is limited, but observational evidence suggests diminishing returns after week 20-24 as VAT reduction plateaus and the body reaches a new homeostatic setpoint. Continuing tesamorelin + ipamorelin blend before and after the initial 24-week cycle without a washout period increases the risk of receptor desensitization (reduced pituitary responsiveness to GHRH and ghrelin signaling) and potential negative feedback suppression of endogenous GH pulsatility. The optimal approach: complete a 12-24 week intensive phase, then transition to a maintenance protocol—tesamorelin 1mg three times weekly plus ipamorelin 200mcg once daily for 8-12 weeks, followed by a 4-6 week complete washout before resuming. This preserves receptor sensitivity and allows endogenous GH secretion patterns to normalize.

Do not initiate tesamorelin or ipamorelin if baseline IGF-1 exceeds 275 ng/mL without medical supervision. Elevated IGF-1 suggests either pre-existing GH hypersecretion (pituitary adenoma, acromegaly) or exogenous GH use—adding GHRH or ghrelin agonists in this context risks pushing IGF-1 into supra-physiological ranges (>350 ng/mL) associated with increased cancer proliferation risk, insulin resistance, and soft tissue overgrowth. Obtain pituitary MRI and endocrinology consultation if IGF-1 is elevated without known cause. If you're concurrently using other growth-promoting compounds like IGF-1 LR3, discontinue those agents for 4-6 weeks and retest before starting the tesamorelin + ipamorelin blend.

Joint discomfort and mild carpal tunnel syndrome (numbness, tingling in the hands, especially nocturnal) occur in approximately 8-12% of users at higher tesamorelin doses and reflect fluid retention from GH-induced sodium retention and soft tissue edema. Reduce tesamorelin dose by 25-50% (from 2mg to 1-1.5mg daily) and reassess after 7-10 days—symptoms typically resolve without discontinuation. Increasing potassium intake modestly (through dietary sources like leafy greens, avocado, or potassium chloride supplementation at 200-400mg daily) can offset sodium retention. If symptoms persist beyond 2 weeks at reduced dose, discontinue tesamorelin and consider ipamorelin monotherapy, which carries significantly lower edema risk due to lower sustained GH elevation.

This is the expected outcome. You're losing visceral fat while gaining lean mass. A DEXA scan would show body composition shift even if total weight remains stable. VAT reduction of 10cm² paired with 0.5kg lean mass gain produces no scale movement but measurable waist circumference change of 1–2 inches. This is why waist-to-hip ratio and DEXA are better markers than BMI for combination therapy. The protocol is working exactly as designed.

These are dose-dependent side effects of sustained GH elevation. They indicate you're using pharmaceutical-grade peptides at effective concentrations, but the dose exceeds your tolerance threshold. Reduce tesamorelin to 0.75mg and ipamorelin to 200mcg, maintaining the same timing and frequency. Symptoms typically resolve within 5–7 days at the lower dose. If they persist, discontinue for 10 days to allow GH levels to normalize, then restart at 50% dose and titrate upward over 4 weeks.

Verify peptide storage temperature immediately. Reconstituted peptides stored above 4°C lose 20–40% potency within 10 days, which delays visible results by 4–6 weeks. Check injection timing: administering the blend within 2 hours of a high-carbohydrate meal blunts GH release by 60% due to insulin interference. If both factors are correct, the issue is likely caloric intake. GH elevation mobilizes fat, but without a 300–500 calorie daily deficit, mobilized fatty acids are re-stored rather than oxidized. Adjust dietary structure before adjusting dose.